|
Title |
Issue |
|
|
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. |
Breast Cancer . 2023 Nov;30(6):872-884. doi: 10.1007/s12282-023-01505-x. |
|
|
The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition. |
Breast Cancer . 2024 Jan;31(1):1-7. doi: 10.1007/s12282-023-01510-0. |
|
|
The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition. |
Breast Cancer . 2024 May;31(3):347-357. doi: 10.1007/s12282-024-01568-4. |
|
|
The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition. |
Breast Cancer . 2024 Jan;31(1):8-15. doi: 10.1007/s12282-023-01518-6. |
|
|
The Japanese breast cancer society clinical practice guidelines for breast cancer screening and diagnosis, 2022 edition. |
Breast Cancer . 2024 Mar;31(2):157-164. doi: 10.1007/s12282-023-01521-x. |
|
|
The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition. |
Breast Cancer . 2024 Mar;31(2):166-178. doi: 10.1007/s12282-023-01531-9. |
|
|
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. |
Breast Cancer . 2024 May;31(3):340-346. doi: 10.1007/s12282-024-01566-6. |
|
|
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. |
Breast Cancer . 2024 May;31(3):335-339. doi: 10.1007/s12282-024-01550-0. |
|
|
Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition. |
Breast Cancer . 2023 Jul;30(4):519-530. doi: 10.1007/s12282-023-01455-4. |
